MAM
OVID icon

Meeder Asset Management’s Ovid Therapeutics OVID Stock Holding History

Meeder Asset Management’s Portfolio OVID Stock Details OVID Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-716
Closed -$1K – 2112
2019
Q1 		$1K Hold
716
– – ﹤0.01% 1634
2018
Q4 		$2K Buy
716
+90
+14% +$411 ﹤0.01% 1582
2018
Q3 		$3K Buy
626
+264
+73% +$2K ﹤0.01% 1410
2018
Q2 		$2.82K Buy
362
+71
+24% +$609 ﹤0.01% 1367
2018
Q1 		$2K Buy
291
+203
+231% +$1.64K ﹤0.01% 1387
2017
Q4 		$1K Buy
+88
New +$808 ﹤0.01% 1581

Other funds holding OVID

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CI
Cowen Inc New York $1.39B AUM 60.14% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
GPCM
Granite Point Capital Management Boston, Massachusetts $4.9M AUM 38.41% 1-Year Est. Return
TCM
Tekla Capital Management Boston, Massachusetts $2.56B AUM 18.15% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
AC
AWH Capital Dallas, Texas $110M AUM 44.24% 1-Year Est. Return

Meeder Asset Management's OVID Position: Q2 2019 in Review

Meeder Asset Management sold out of Ovid Therapeutics (OVID) in Q2 2019, closing a stake of 716 shares — an estimated $1K sold.

Meeder Asset Management first reported a position in OVID in Q4 2017 and held it in 6 quarters. The position peaked at $3K in Q3 2018. 35 funds tracked by Wall St. Rank hold OVID as of Q2 2019.

  • Meeder Asset Management reported no remaining Ovid Therapeutics position as of Q2 2019 after selling out during the quarter.
  • Meeder Asset Management sold 716 Ovid Therapeutics shares in Q2 2019, an estimated $1K.
  • Meeder Asset Management first reported a position in Ovid Therapeutics in Q4 2017 and held it in 6 quarters.
  • Meeder Asset Management's Ovid Therapeutics position peaked at $3K in Q3 2018.
  • 35 funds tracked by Wall St. Rank held Ovid Therapeutics as of Q2 2019.

Based on Meeder Asset Management's 13F filing for Q2 2019, filed 5 Aug 2019.